刺激后血单核细胞TNF水平可预测IBD患者英夫利昔应答
该前瞻性研究纳入41例未用过生物制剂的IBD患者,在首次英夫利昔输注前检测脂多糖刺激的外周血单核细胞(PBMC)TNF产量,第6周评估临床应答。应答者基线PBMC产生的TNF和IL6显著高于无应答者;TNF 500 pg/ml可区分应答者(敏感性82%、特异性78%),在克罗恩病中敏感性100%、特异性82%。
要点
- 基线刺激后PBMC TNF水平高者更可能对英夫利昔产生临床应答。
- TNF 500 pg/ml为 cutoff,总体敏感性82%、特异性78%。
- 克罗恩病患者中该 cutoff 敏感性100%、特异性82%。
核心结论
- IBD患者PBMC(尤其CD14+细胞)受刺激后产生高水平TNF可识别最可能对英夫利昔治疗产生临床应答者。
研究设计与样本
- 前瞻性研究纳入41例未用过生物制剂的IBD成人(平均年龄38岁,21例男性,21例克罗恩病、20例溃疡性结肠炎),在德国柏林首次英夫利昔输注前采集基线PBMC,并设10名健康对照。
主要发现
- 应答者中位病程短于无应答者(P = .018),中位Limberg评分高于无应答者(P = .021)。
- 应答者基线PBMC产生的TNF显著高于无应答者(P = .049),IL6也显著更高(P = .028)。
- 500 pg/ml TNF区分应答者的敏感性为82%、特异性为78%。
- 克罗恩病患者中500 pg/ml TNF区分应答者的敏感性为100%、特异性为82%。
- 多因素分析中高于该水平的TNF与英夫利昔应答独立相关(OR 16.2;95%CI 1.8-148.7;P = .014)。
关键数值与推荐
- 主要终点为第6周临床应答:Harvey Bradshaw指数下降≥2分或部分Mayo评分下降≥3分。
- TNF cutoff 500 pg/ml:总体敏感性82%、特异性78%;克罗恩病中敏感性100%、特异性82%。
临床怎么用
- 对未用过生物制剂的IBD患者,可考虑在首次英夫利昔前检测刺激后PBMC TNF水平,以辅助预判临床应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: A substantial proportion patients with inflammatory bowel disease (IBD) have a primary non-response to infliximab; markers are needed to identify patients most likely to respond to treatment. We investigated whether production of tumor necrosis factor (TNF) by peripheral blood mononuclear cells (PBMCs) can be used as a marker to predict response. METHODS: We performed a prospective study of 41 adults with IBD (mean age, 38 years; 21 male; 21 with Crohn's disease and 20 with ulcerative colitis) not treated with a biologic agent within the past 6 months; patients were given their first infusion of infliximab at a hospital or clinic in Berlin, Germany. We collected data on clinical scores, levels of C-reactive protein, and ultrasound results (Limberg scores) at baseline (before the first infusion) and after 6 weeks (3rd infliximab infusion). PMBCs were obtained from patients at baseline and 10 healthy individuals (controls) and incubated with lipopolysaccharide. We measured production of cytokines (TNF, interleukin 1 [IL1], IL6, IL8, IL10, IL12p70, and IL22) by ELISA and performed cytometric bead array and flow cytometry analyses. The primary endpoint was clinical response (decrease in Harvey Bradshaw Index scores of 2 or more or decrease in partial Mayo scores of 3 or more at week 6) in patients with PBMCs that produced high vs low levels of TNF. RESULTS: Responders had a shorter median disease duration (P = .018) and higher median Limberg score (P = .021), than nonresponders. Baseline PBMCs from responders produced significantly more TNF (P = .049) and IL6 (P = .028) than from nonresponders; a level of 500 pg/ml TNF identified responders with 82% sensitivity and 78% specificity. In patients with Crohn's disease, this cutoff value (500 pg/ml TNF) identified responders with 100% sensitivity and 82% specificity; TNF levels above this level were independently associated with response to infliximab in multivariate analysis (odds ratio, 16.2; 95% CI, 1.8-148.7; P = .014). The percentage of TNF-positive cells was higher among CD14+ monocytes than lymphocytes after stimulation. CONCLUSIONS: Production of a high level of TNF by PBMCs (specifically CD14+ cells) from patients with IBD can identify those most likely to have a clinical response to infliximab therapy. In patients with Crohn's disease, a cutoff value of 500 pg/ml TNF identified responders with 100% sensitivity and 82% specificity.
引用
- Jessen B, Rodriguez-Sillke Y, Sonnenberg E, et al. Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab. Clin Gastroenterol Hepatol. 2020. PMID: 32272247. doi:10.1016/j.cgh.2020.03.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。